Beyond Glucose: Scaling a Multi-VOC Breath Platform to Unlock Fat Burn Insights at Scale
ABSTRACT
BOYDSense is developing a non-invasive, portable handheld breath-analyzer that detects and measures specific volatile organic compounds (VOCs) in exhaled breath using proprietary sensors and algorithms to track biomarkers for chronic conditions, without requiring blood samples or finger pricks.
For more than 2 billion people managing diabetes, prediabetes, or obesity, monitoring glucose is important, but tracking fat burn can provide additional insights, as it correlates strongly with weight loss efforts and GLP-1 treatments. Yet no convenient tool currently measures it. Finger pricks and CGMs report glucose, leaving more than 1 billion consumers without insight into whether their bodies are burning fat.
BOYDSense addresses this gap with a proprietary multi-biomarker MOx sensor platform that detects more than 100 metabolic VOC fingerprints in a single breath, including acetone and other metabolism markers. Combined with a miniaturized sampling module and embedded AI algorithm, the platform moves beyond single-analyte detection toward a defensible multi-biomarker solution protected by nine patent families. BOYDSense reflects the industry’s shift from component-level sensing innovation to scalable sensing solutions that enable new medical applications, fully non-invasive.
The platform has already achieved 94% correct classification, supported by four clinical trials, more than 390 subjects, and over 4,900 lab-verified datasets, as well as BOYDSense’s first peer-reviewed glucose publication in the Journal of Diabetes Science and Technology in 2026.
This evidence is now translating into commercial value, with four signed distribution LOIs and additional partners in negotiation. BOYDSense’s first breath analyzer for fat-burning insight offers a clear case study in scaling from sensor-level innovation and advanced algorithms to deployed applications.
BIOGRAPHY
Bruno Thuillier is Founder & CEO of BOYDSense, where he is turning breath-based sensing into a scalable metabolic-health platform. His career is a throughline from sensor innovation to commercial value: as CTO of Sensitive Object (acquired by TE Connectivity, NYSE: TEL), he brought touch-sensor technology to demanding environments including medical, and as VP of R&D at Siemens Mobile he led global teams that helped establish the company as a tier-1 player. Earlier roles at AT&T and Loewe Technology scaled digital voice, video, and data systems across the early mobile-device market in London and Hong Kong. A holder of multiple patents in user-interface and biosensor innovation, Bruno pairs deep sensing expertise with an entrepreneurial, international outlook. He holds dual French-U.S. citizenship, studied physics, and is based in San Francisco.